vs
Side-by-side financial comparison of Angel Oak Mortgage REIT, Inc. (AOMR) and Protalix BioTherapeutics, Inc. (PLX). Click either name above to swap in a different company.
Angel Oak Mortgage REIT, Inc. is the larger business by last-quarter revenue ($10.9M vs $9.1M, roughly 1.2× Protalix BioTherapeutics, Inc.). Angel Oak Mortgage REIT, Inc. runs the higher net margin — 103.9% vs -60.3%, a 164.2% gap on every dollar of revenue. On growth, Angel Oak Mortgage REIT, Inc. posted the faster year-over-year revenue change (10.4% vs -49.9%). Over the past eight quarters, Angel Oak Mortgage REIT, Inc.'s revenue compounded faster (12.7% CAGR vs -6.7%).
Angel Oak Mortgage REIT, Inc. is a U.S.-based real estate investment trust focused on investing in residential mortgage assets, including non-agency mortgage-backed securities, residential mortgage loans, and credit-linked real estate instruments. It serves U.S. institutional and retail investors, targeting competitive risk-adjusted returns through regular income and long-term capital growth.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
AOMR vs PLX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.9M | $9.1M |
| Net Profit | $11.3M | $-5.5M |
| Gross Margin | — | 49.4% |
| Operating Margin | — | -51.1% |
| Net Margin | 103.9% | -60.3% |
| Revenue YoY | 10.4% | -49.9% |
| Net Profit YoY | 175.2% | -184.8% |
| EPS (diluted) | $0.44 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $10.9M | $9.1M | ||
| Q3 25 | $10.2M | $17.9M | ||
| Q2 25 | $9.9M | $15.7M | ||
| Q1 25 | $10.1M | $10.1M | ||
| Q4 24 | $9.9M | $18.2M | ||
| Q3 24 | $9.0M | $18.0M | ||
| Q2 24 | $9.5M | $13.5M | ||
| Q1 24 | $8.6M | — |
| Q4 25 | $11.3M | $-5.5M | ||
| Q3 25 | $11.4M | $2.4M | ||
| Q2 25 | $767.0K | $164.0K | ||
| Q1 25 | $20.5M | $-3.6M | ||
| Q4 24 | $-15.1M | $6.5M | ||
| Q3 24 | $31.2M | $3.2M | ||
| Q2 24 | $-273.0K | $-2.2M | ||
| Q1 24 | $12.9M | — |
| Q4 25 | — | 49.4% | ||
| Q3 25 | — | 53.4% | ||
| Q2 25 | — | 62.5% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 53.4% | ||
| Q2 24 | — | 29.8% | ||
| Q1 24 | — | — |
| Q4 25 | — | -51.1% | ||
| Q3 25 | — | 11.9% | ||
| Q2 25 | 7.7% | 7.5% | ||
| Q1 25 | — | -41.0% | ||
| Q4 24 | -152.6% | 39.6% | ||
| Q3 24 | — | 22.2% | ||
| Q2 24 | -1.4% | -18.0% | ||
| Q1 24 | — | — |
| Q4 25 | 103.9% | -60.3% | ||
| Q3 25 | 112.1% | 13.2% | ||
| Q2 25 | 7.7% | 1.0% | ||
| Q1 25 | 203.5% | -35.8% | ||
| Q4 24 | -152.6% | 35.6% | ||
| Q3 24 | 345.9% | 18.0% | ||
| Q2 24 | -2.9% | -16.4% | ||
| Q1 24 | 150.1% | — |
| Q4 25 | $0.44 | $-0.06 | ||
| Q3 25 | $0.46 | $0.03 | ||
| Q2 25 | $0.03 | $0.00 | ||
| Q1 25 | $0.87 | $-0.05 | ||
| Q4 24 | $-0.62 | $0.10 | ||
| Q3 24 | $1.29 | $0.03 | ||
| Q2 24 | $-0.01 | $-0.03 | ||
| Q1 24 | $0.51 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $41.6M | $14.7M |
| Total DebtLower is stronger | $2.3B | — |
| Stockholders' EquityBook value | $267.5M | $48.2M |
| Total Assets | $2.7B | $82.3M |
| Debt / EquityLower = less leverage | 8.51× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $41.6M | $14.7M | ||
| Q3 25 | $51.6M | $13.6M | ||
| Q2 25 | $40.5M | $17.9M | ||
| Q1 25 | $38.7M | $19.5M | ||
| Q4 24 | $40.8M | $19.8M | ||
| Q3 24 | $42.1M | $27.4M | ||
| Q2 24 | $44.0M | $23.4M | ||
| Q1 24 | $39.4M | — |
| Q4 25 | $2.3B | — | ||
| Q3 25 | $2.2B | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $1.8B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $267.5M | $48.2M | ||
| Q3 25 | $264.2M | $52.9M | ||
| Q2 25 | $246.4M | $49.9M | ||
| Q1 25 | $251.5M | $45.2M | ||
| Q4 24 | $239.0M | $43.2M | ||
| Q3 24 | $265.1M | $32.4M | ||
| Q2 24 | $255.8M | $28.6M | ||
| Q1 24 | $263.3M | — |
| Q4 25 | $2.7B | $82.3M | ||
| Q3 25 | $2.6B | $82.3M | ||
| Q2 25 | $2.6B | $78.5M | ||
| Q1 25 | $2.7B | $73.9M | ||
| Q4 24 | $2.3B | $73.4M | ||
| Q3 24 | $2.3B | $61.6M | ||
| Q2 24 | $2.1B | $91.5M | ||
| Q1 24 | $2.3B | — |
| Q4 25 | 8.51× | — | ||
| Q3 25 | 8.37× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 7.62× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-407.0M | $2.0M |
| Free Cash FlowOCF − Capex | — | $1.6M |
| FCF MarginFCF / Revenue | — | 17.8% |
| Capex IntensityCapex / Revenue | — | 4.4% |
| Cash ConversionOCF / Net Profit | -35.96× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-13.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-407.0M | $2.0M | ||
| Q3 25 | $-173.4M | $-3.7M | ||
| Q2 25 | $20.6M | $-5.2M | ||
| Q1 25 | $-201.7M | $-5.1M | ||
| Q4 24 | $-221.5M | $4.0M | ||
| Q3 24 | $-212.4M | $4.1M | ||
| Q2 24 | $-24.2M | $-3.6M | ||
| Q1 24 | $40.2M | — |
| Q4 25 | — | $1.6M | ||
| Q3 25 | — | $-4.2M | ||
| Q2 25 | — | $-5.7M | ||
| Q1 25 | — | $-5.4M | ||
| Q4 24 | — | $3.6M | ||
| Q3 24 | — | $4.0M | ||
| Q2 24 | — | $-3.8M | ||
| Q1 24 | — | — |
| Q4 25 | — | 17.8% | ||
| Q3 25 | — | -23.7% | ||
| Q2 25 | — | -36.2% | ||
| Q1 25 | — | -53.0% | ||
| Q4 24 | — | 19.6% | ||
| Q3 24 | — | 22.4% | ||
| Q2 24 | — | -28.1% | ||
| Q1 24 | — | — |
| Q4 25 | — | 4.4% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | — | 2.8% | ||
| Q1 25 | — | 3.0% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 0.5% | ||
| Q2 24 | — | 1.3% | ||
| Q1 24 | — | — |
| Q4 25 | -35.96× | — | ||
| Q3 25 | -15.19× | -1.58× | ||
| Q2 25 | 26.92× | -31.91× | ||
| Q1 25 | -9.83× | — | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | -6.81× | 1.27× | ||
| Q2 24 | — | — | ||
| Q1 24 | 3.12× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AOMR
| Nonrelated Party | $6.4M | 59% |
| Other | $4.5M | 41% |
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
